These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 30467877

  • 1. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E, Trinh S, Trinh H, Nguyen H, Nguyen K, Do A, Levitt B, Do S, Nguyen M, Purohit T, Shieh E, Nguyen MH.
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [Abstract] [Full Text] [Related]

  • 2. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J.
    PLoS One; 2019 Jan; 14(4):e0214795. PubMed ID: 30946776
    [Abstract] [Full Text] [Related]

  • 3. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS, RESCUE and ACTG A5348 study investigators.
    Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z, Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group.
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, Backus LI.
    Clin Infect Dis; 2017 Jun 15; 64(12):1711-1720. PubMed ID: 28199525
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M.
    J Hepatol; 2019 Oct 15; 71(4):666-672. PubMed ID: 31203153
    [Abstract] [Full Text] [Related]

  • 7. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
    Latt NL, Yanny BT, Gharibian D, Gevorkyan R, Sahota AK.
    World J Gastroenterol; 2017 Jul 14; 23(26):4759-4766. PubMed ID: 28765697
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
    Modi AA, Nazario HE, Gonzales GR, Gonzalez SA.
    Aliment Pharmacol Ther; 2018 May 14; 47(10):1409-1415. PubMed ID: 29569736
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.
    Yanny B, Saab S, Durazo F, Latt N, Mitry A, Mikhail MM, Hanna RM, Aziz A, Sahota A.
    Dig Dis Sci; 2018 Dec 14; 63(12):3480-3486. PubMed ID: 30259281
    [Abstract] [Full Text] [Related]

  • 14. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI.
    J Hepatol; 2019 Jan 14; 70(1):15-23. PubMed ID: 30266283
    [Abstract] [Full Text] [Related]

  • 15. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
    Belperio PS, Shahoumian TA, Loomis TP, Backus LI.
    J Viral Hepat; 2019 Aug 14; 26(8):980-990. PubMed ID: 31012179
    [Abstract] [Full Text] [Related]

  • 16. Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
    Shin HP, Burman B, Kozarek RA, Zeigler A, Wang C, Lee H, Zehr T, Edwards AM, Siddique A.
    Gut Liver; 2017 Sep 15; 11(5):711-720. PubMed ID: 28651301
    [Abstract] [Full Text] [Related]

  • 17. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.
    Babatin MA, AlGhamdi AS, Assiri AM, AlBiladi H, AlOthmani HS, Mogharbel MH, Mahallawi W, Asselah T, Sanai FM.
    Saudi J Gastroenterol; 2019 Sep 15; 25(1):55-60. PubMed ID: 30117490
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S, NAVIGATORE-Lombardia and Veneto Study Groups.
    J Hepatol; 2019 Dec 15; 71(6):1106-1115. PubMed ID: 31433303
    [Abstract] [Full Text] [Related]

  • 20. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H.
    Eur J Gastroenterol Hepatol; 2019 Mar 15; 31(3):382-388. PubMed ID: 30383554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.